SCHEMBL7004439

SCHEMBL7004439

COc1ccc(S(=O)(=O)N(O)C(=O)CCCNCc2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
ATM Q13315 1/20 0.52
BMP1 P13497 4/20 0.51
CXCR3 P49682 2/20 0.50
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 3/20 0.49
MMP3 P08254 1/20 0.47
PTGES O14684 1/20 0.47
TAS2R14 Q9NYV8 1/20 0.47
TAS2R8 Q9NYW2 1/20 0.47
ALOX5 P09917 1/20 0.46
TP53 P04637 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA4 P22748 1/20 0.46
CA9 Q16790 1/20 0.46
HTT P42858 1/20 0.45
CHRM2 P08172 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7112783 0.90 MEN1 (0.57) MEN1KMT2AATMBMP1CXCR3
SCHEMBL7003884 0.84 BMP1 (0.48) MEN1KMT2ABMP1CXCR3MMP3
SCHEMBL6540427 0.74 MEN1 (0.62) MEN1KMT2AATMALDH1A1CA12
SCHEMBL16296132 0.74 CHRM2 (0.66) MEN1KMT2AATMKDM4EALDH1A1
SCHEMBL6540208 0.71 MEN1 (0.73) MEN1KMT2AATMALDH1A1CA12
SCHEMBL8850869 0.71 HDAC3 (0.58) MEN1KMT2AATMKDM4EALDH1A1
SCHEMBL9674448 0.71 NPC1 (0.68) MEN1KMT2AATMALDH1A1
SCHEMBL7001320 0.70 MMP1 (0.55) MEN1KMT2AATMKDM4EALDH1A1
SCHEMBL8340855 0.70 CXCR3 (0.49) BMP1CXCR3ALDH1A1MMP3PTGES
Hydrochloric Acid SCHEMBL3508365 0.70 CHRM2 (0.64) MEN1KMT2AATMKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191309-A1 N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production HO WEN-BIN (US) 2003-10-09 US disclosed
EP-1154992-A4 N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION FIBROGEN INC (US) 2003-05-28 EP disclosed
US-6506936-B1 Treating fibrotic disorder selected from hepatic cirrhosis and arthritis; inhibiting matrix metalloproteases FIBROGEN, INC. 2003-01-14 US disclosed
EP-1154992-A1 N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION FIBROGEN, INC. (US) 2001-11-21 EP disclosed
WO-2000050390-A1 N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION FIBROGEN, INC. (US) 2000-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191309-A1 N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production MMP1, MMP13, COL14A1 MEN1 4787/4885KMT2A 1817/4885ATM 4121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.